Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · IEX Real-Time Price · USD
6.22
+0.16 (2.64%)
At close: May 9, 2024, 4:00 PM
6.17
-0.05 (-0.80%)
After-hours: May 9, 2024, 7:58 PM EDT

Fractyl Health Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Fractyl Health stock has a target of 18, which predicts an increase of 189.39% from the current stock price of 6.22.

Analyst Consensus: Buy
Target Low Average Median High
Price $18 $18 $18 $18
Change +189.39% +189.39% +189.39% +189.39%
* Price targets were last updated on Feb 27, 2024.

Analyst Ratings

The average analyst rating for Fractyl Health stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Mar '24Apr '24May '24
Strong Buy 000
Buy 222
Hold 000
Sell 000
Strong Sell 000
Total 222

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Evercore ISI Group
Evercore ISI Group
Buy
Initiates
n/a
Buy Initiates n/a n/a Feb 28, 2024
Morgan Stanley
Morgan Stanley
Buy
Initiates
$18
Buy Initiates $18 +189.39% Feb 27, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
from 120.00K
Revenue Next Year
5.01M
EPS This Year
-1.92
from -45.29
EPS Next Year
-2.06
from -1.92
Year 202120222023202420252026
Revenue
--120.00K-5.01M12.68M
Revenue Growth
-----153.25%
EPS
-13.34-31.97-45.29-1.92-2.06-2.14
EPS Growth
------
No. Analysts ---443
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202420252026
High n/a 10.3M 13.1M
Avg n/a 5.0M 12.7M
Low n/a n/a 12.2M

Revenue Growth

Revenue Growth 202420252026
High - -
160.7%
Avg - -
153.3%
Low - -
143.3%

EPS Forecast

EPS 202420252026
High -1.47 -1.86 -2.21
Avg -1.92 -2.06 -2.14
Low -2.31 -2.21 -2.06

EPS Growth

EPS Growth 202420252026
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.